Skip to navigation Skip to main content

Your search for apixaban returned 81 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove

Your search for apixaban returned 81 results

Sort Results:

Relevant Recent
News

Prophylaxis With Apixaban Feasible for Cancer Patients

Publish Date
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
News

Apixaban Beats Aspirin for Stroke Prevention in A-Fib

Publish Date
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
Drugs in the Pipeline

Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study

Publish Date
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News

Safety of Direct Oral Anticoagulants Versus Warfarin Investigated

Publish Date
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.